National Pension Service Grows Holdings in Edwards Lifesciences Corporation $EW

National Pension Service raised its position in Edwards Lifesciences Corporation (NYSE:EW) by 0.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 899,689 shares of the medical research company’s stock after buying an additional 6,870 shares during the period. National Pension Service’s holdings in Edwards Lifesciences were worth $70,365,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of EW. Jennison Associates LLC lifted its stake in shares of Edwards Lifesciences by 15.7% in the second quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after acquiring an additional 1,584,958 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Edwards Lifesciences by 4.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock worth $491,673,000 after purchasing an additional 264,311 shares during the last quarter. Nuveen LLC purchased a new stake in Edwards Lifesciences during the 1st quarter worth approximately $330,881,000. Invesco Ltd. raised its position in shares of Edwards Lifesciences by 2.6% in the 1st quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock valued at $310,773,000 after purchasing an additional 107,241 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Edwards Lifesciences by 5.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock worth $287,140,000 after buying an additional 198,882 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of the business’s stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,816,265.10. This trade represents a 4.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 22,970 shares of company stock valued at $1,862,878 over the last 90 days. 0.34% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

EW has been the subject of several research analyst reports. Barclays reissued an “overweight” rating and issued a $99.00 target price (up previously from $95.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. The Goldman Sachs Group set a $104.00 price objective on Edwards Lifesciences and gave the company a “buy” rating in a report on Friday, October 31st. Oppenheimer downgraded Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a report on Wednesday, October 8th. UBS Group reiterated a “neutral” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a research report on Monday, November 3rd. Finally, JPMorgan Chase & Co. increased their target price on shares of Edwards Lifesciences from $85.00 to $90.00 and gave the stock a “neutral” rating in a report on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus price target of $91.39.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $86.17 on Friday. Edwards Lifesciences Corporation has a 12-month low of $65.31 and a 12-month high of $87.21. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The firm has a market capitalization of $50.00 billion, a price-to-earnings ratio of 12.40, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03. The business has a 50 day simple moving average of $78.09 and a 200 day simple moving average of $77.65.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same quarter in the previous year, the firm posted $0.67 EPS. The firm’s quarterly revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.